Holen Sie sich die Stockscreener-App
1.7195
12.71%
-0.2405
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen Q4 2025 Earnings Call Transcript - MarketBeat
Ocugen 2025 Financial Results: Quarterly and Annual ReportNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ocugen files petition in Delaware court to validate share increase amendment - Investing.com Nigeria
Ocugen (OCGN) Advances Gene Therapy Trials and Strengthens Leade - GuruFocus
Ocugen (NASDAQ:OCGN) Shares Gap DownWhat's Next? - MarketBeat
Ocugen (OCGN) Reports Q4 Earnings and Cash Position Update - GuruFocus
Ocugen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results - Ocugen, Inc.
Ocugen 10-K: Revenue $4.4M, Net Loss $67.8M - TradingView
Ocugen (NASDAQ: OCGN) advances RP, GA and Stargardt gene therapies - Stock Titan
Ocugen Seeks Court Validation of Charter Amendment Dispute - TipRanks
Ocugen (NASDAQ:OCGN) Announces Earnings Results - MarketBeat
Court petition over Ocugen (NASDAQ: OCGN) share increase vote - Stock Titan
Ocugen (NASDAQ: OCGN) advances eye gene therapies and extends cash runway - Stock Titan
Ocugen, Inc. completes OCU400 Phase 3 and secures first OCU400 licensing deal amid leadership boost - Traders Union
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com Nigeria
Ocugen Q4 Earnings Call Highlights - Yahoo Finance
OCGN: Advanced gene therapy pipeline, strong clinical data, and extended cash runway into late 2026 - TradingView
OCGN: OCU400 Phase 3 enrollment completed; strong pipeline progress and extended cash runway - TradingView
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ocugen (OCGN) Achieves Significant Milestones in 2025 - GuruFocus
OCUGEN ($OCGN) Releases Q4 2025 Earnings - Quiver Quantitative
OCGN: Advanced gene therapy pipeline and secured financing, extending cash runway into late 2026 - TradingView
Ocugen Completes Enrollment in OCU400 Phase 3 Clinical Trial for Retinitis Pigmentosa, Prepares for Major 2027 Data Announcements - Quiver Quantitative
Earnings Summary: Ocugen Q4 - Benzinga
BRIEF-Ocugen Q4 EPS USD -0.06 - TradingView
Gene therapy push for blindness: how Ocugen plans to fund it - Stock Titan
OCGN Earnings History & Surprises | EPS & Revenue Results | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen: Fourth Quarter Financial Results Overview - Bitget
Examining the Future: Ocugen's Earnings Outlook - Benzinga
OCGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Ocugen (NASDAQ:OCGN) Sets New 1-Year HighStill a Buy? - MarketBeat
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Key facts: Ocugen completes patient enrollment for OCU400 trial; 6-cent loss per share expected - TradingView
Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete - TipRanks
Ocugen completes enrollment in phase 3 retinitis pigmentosa trial - Investing.com
Ocugen Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Ocugen (OCGN) Completes Enrollment for Phase 3 OCU400 Trial - GuruFocus
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa - Bitget
Ocugen, Inc. advances gene therapies for rare inherited retinal diseases amid global support - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharm - StreetInsider
Ocugen Advances Toward Key Regulatory Submission for Gene Therapy - AD HOC NEWS
How The Investment Story For Ocugen (OCGN) Is Shifting With New Data And Funding Moves - Yahoo Finance
Why Did OCGN Stock Rise Today? - Asianet Newsable
Investment Report: Is Ocugen Inc undervalued by DCF analysisJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Ocugen (OCGN) Expected to Announce Earnings on Wednesday - MarketBeat
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen to Host March 4 Call on Q4 and Full-Year 2025 Results - MyChesCo
Q1 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen (NASDAQ:OCGN) Trading 6.6% HigherHere's Why - MarketBeat
Risk Analysis: Is Ocugen Inc a cyclical or defensive stockWeekly Stock Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Will Ocugen Inc. stock split again soonJuly 2025 Weekly Recap & Weekly Top Stock Performers List - mfd.ru
Profit Review: Is RILY attractive at current valuationWeekly Trade Review & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen appoints Rita Johnson-Greene as chief financial officer - MSN
4.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):